Technological strategies for amphotericin B formulations in lipid systems available in the pharmaceutical market and other promising delivery systems

Authors

  • Gustavo Julio Borges Arruda Faculdade de Ciências Farmacêuticas de Araraquara - FCFar/UNESP Rodovia Araraquara-Jaú km 1, Campus Ville Araraquara/SP CEP-14801-902 Tel: (16)3301-6961
  • Gustavo Rossanezi Faculdade de Ciências Farmacêuticas de Araraquara - FCFar/UNESP Rodovia Araraquara-Jaú km 1, Campus Ville Araraquara/SP CEP-14801-902 Tel: (16)3301-6961
  • Maria Virginia Scarpa Faculdade de Ciências Farmacêuticas de Araraquara - FCFar/UNESP Rodovia Araraquara-Jaú km 1, Campus Ville Araraquara/SP CEP-14801-902 Tel: (16)3301-6961
  • Erivaldo Socrates Tabosa do Egito Departamento de Farmácia, Centro de Ciências da Saúde, Universidade Federal do Rio Grande do Norte Rua Gal. Gustavo Cordeiro de Farias, S/N , Petrópolis Natal/RN CEP 59010-180 Tel: (84) 3342-9808 ramal 9817
  • Anselmo Gomes de Oliveira Faculdade de Ciências Farmacêuticas de Araraquara - FCFar/UNESP Rodovia Araraquara-Jaú km 1, Campus Ville Araraquara/SP CEP-14801-902 Tel: (16)3301-6961 / 6974

DOI:

https://doi.org/10.14450/2318-9312.v28.e2.a2016.pp59-67

Keywords:

amphotericin B, drug delivery systems, solubility, toxicity, systemic antifungal

Abstract

Amphotericin B (AmB) is an antifungal reference drug in treatment of systemic mycoses since its discovery in the years 1950. The aim of this study was to establish the state of the art of the technological strategies involved in the
administration drug dosage forms AmB and the the paths for intervention to improve the drug solubility, allowing its administration intravenously and minimize its toxicity. The importance of the studies to the medical-pharmaceutical field is related to new drug delivery systems that can increase membership by children and the elderly, in addition to increasing the therapeutic arsenal available to the medical clinic. Due the limited clinical utility of the normal AmB formulations because of its high toxicity, the new administration systems of AmB able to direct the antibiotic directly to site of infections has been the most studied. Therefore, the need for different vehicles other than the deoxycholate (Fungizon ®) has been the most common alternative. The lipid formulations have been shown to be more effective and less toxic when compared to AmB deoxycholate, but not yet introduced to hospital routine for treating deep mycoses.

Author Biographies

Gustavo Julio Borges Arruda, Faculdade de Ciências Farmacêuticas de Araraquara - FCFar/UNESP Rodovia Araraquara-Jaú km 1, Campus Ville Araraquara/SP CEP-14801-902 Tel: (16)3301-6961

Ciências Farmacêuticas, Departamento de Fármacos e Medicamento

Gustavo Rossanezi, Faculdade de Ciências Farmacêuticas de Araraquara - FCFar/UNESP Rodovia Araraquara-Jaú km 1, Campus Ville Araraquara/SP CEP-14801-902 Tel: (16)3301-6961

Ciências Farmacêuticas, Farmacotecnia - Departamento de Fármacos e Medicamentos

Maria Virginia Scarpa, Faculdade de Ciências Farmacêuticas de Araraquara - FCFar/UNESP Rodovia Araraquara-Jaú km 1, Campus Ville Araraquara/SP CEP-14801-902 Tel: (16)3301-6961

Ciências Farmacêuticas, Farmacotenia, Departamento de Fármacos e Medicamentos

Erivaldo Socrates Tabosa do Egito, Departamento de Farmácia, Centro de Ciências da Saúde, Universidade Federal do Rio Grande do Norte Rua Gal. Gustavo Cordeiro de Farias, S/N , Petrópolis Natal/RN CEP 59010-180 Tel: (84) 3342-9808 ramal 9817

Departamento de Farmácia, Ciências Farmacêuticas, Farmacotecnia

Anselmo Gomes de Oliveira, Faculdade de Ciências Farmacêuticas de Araraquara - FCFar/UNESP Rodovia Araraquara-Jaú km 1, Campus Ville Araraquara/SP CEP-14801-902 Tel: (16)3301-6961 / 6974

Departamento de Fármacos e Medicamentos - Farmacotecnia, Ciências Farmacêuticas

Published

2016-07-05

How to Cite

Arruda, G. J. B., Rossanezi, G., Scarpa, M. V., Egito, E. S. T. do, & Oliveira, A. G. de. (2016). Technological strategies for amphotericin B formulations in lipid systems available in the pharmaceutical market and other promising delivery systems. Infarma - Pharmaceutical Sciences, 28(2), 59–67. https://doi.org/10.14450/2318-9312.v28.e2.a2016.pp59-67

Issue

Section

Review Article